Marc Frahm
Stock Analyst at TD Cowen
(0.19)
# 4,456
Out of 5,135 analysts
15
Total ratings
16.67%
Success rate
-20.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Buy | $101 → $128 | $102.99 | +24.28% | 4 | Jan 13, 2026 | |
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $3.93 | - | 2 | Jan 8, 2025 | |
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $19.17 | -53.05% | 3 | Aug 6, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $12.44 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.57 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $102.36 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $13.21 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $11.56 | - | 1 | Jun 21, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.26 | - | 1 | Feb 24, 2020 |
Incyte
Jan 13, 2026
Maintains: Buy
Price Target: $101 → $128
Current: $102.99
Upside: +24.28%
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $3.93
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $19.17
Upside: -53.05%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.44
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.57
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $102.36
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.21
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.56
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.26
Upside: -